Clinical Trial Update: Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS) [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy results for pagoclone in treating Persistent Developmental Stuttering, based on completed clinical trial data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Developmental Stuttering

Drugs mentioned

• Pagoclone (pagoclone)

Snippet

Sponsor: Pharmacology Research Institute | Conditions: Persistent Developmental Stuttering | Phase 2 | Status: COMPLETED